Riskpilot← Back to searchSign inGet full accessImmunscape AB
ABIn liquidationOrg 5590700612UmeåResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20160 employees
Revenue 2025
SEK 0
EBITDA margin
—
+89% vs 2024
Equity ratio
15.8%
Financial strength
Net profit 2025
SEK -104K
+51% vs 2024
| Revenue | SEK 0 | — |
| EBITDA | SEK -24K | +89% |
| Net profit | SEK -104K | +51% |
| Total assets | SEK 321K | -25% |
| Equity | SEK 51K | -80% |
| Employees | 0 | — |
Legal name
Immunscape AB
Org number
5590700612
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
13 juli 2016
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-02-28
Financial year
January – December
Signatory rights
Firman tecknas ensam av likvidatorn Firman tecknas var för sig av externa firmatecknarna
Company purpose
Bolaget skall utveckla, förvärva och försälja läkemedelsprodukter och bedriva uppdragsforskning samt därmed förenlig verksamhet.
Address
Umeå
Email
info@heinestams.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 4 951 | 2 555 | 1 024 | 259 | 0 | 0 | 24 | 0 |
| Staff expenses | — | — | — | — | — | — | — | — | −0 |
| EBITDA | 406 | 194 | 228 | −139 | 123 | −69 | −55 | −213 | −24 |
| Depreciation & amort. | −100 | −151 | −221 | −121 | −70 | −0 | −0 | −0 | — |
| EBIT | 306 | 43 | 7 | −260 | 53 | −69 | −55 | −213 | −24 |
| Net financials | — | — | — | — | — | — | — | — | −80 |
| Profit before tax | 230 | 27 | 7 | −168 | 53 | −69 | −55 | −213 | −104 |
| Tax | −51 | −10 | −5 | −0 | −0 | −0 | −0 | −0 | — |
| Net profit | 179 | 17 | 2 | −168 | 53 | −69 | −55 | −213 | −104 |
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | 1 495 | 2 756 | 2 270 | 638 | 735 | 580 | 525 | 425 | 321 |
| Equity | 229 | 245 | 247 | 79 | 592 | 523 | 468 | 255 | 51 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |
| Short-term debt | 1 189 | 2 419 | 1 931 | 559 | 144 | 58 | 58 | 170 | 270 |
| Total debt | 1 189 | 2 419 | 1 931 | 559 | 144 | 58 | 58 | 170 | 270 |
EBITDA margin
-2369800.0%
This company
15.8%
Market median
-14998834% vs market
20172025
Equity ratio
15.8%
This company
38.2%
Market median
-59% vs market
20172025
Return on equity
-206.2%
This company
18.4%
Market median
-1221% vs market
20172025
Net profit margin
-10414300.0%
This company
8.1%
Market median
-128571705% vs market
20172025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20172025
Debt / equity
5.35×
This company
0.62×
Market median
-763% vs market
20172025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-03-01 – 2025-02-28
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-03-01 – 2024-02-29
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-03-01 – 2023-02-28
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-03-01 – 2022-02-28
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-03-01 – 2021-02-28
- Annual report 2020Filed via Bolagsverket / SCB · Period 2019-03-01 – 2020-02-29
- Annual report 2019Filed via Bolagsverket / SCB · Period 2018-03-01 – 2019-02-28
- Annual report 2018Filed via Bolagsverket / SCB · Period 2017-03-01 – 2018-02-28
- Annual report 2017Filed via Bolagsverket / SCB · Period 2016-07-01 – 2017-02-28
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
EJ External Signatory | External Signatory | 2026 | — | — |
SM External Signatory | External Signatory | 2026 | — | — |
EF External Signatory | External Signatory | 2026 | — | — |
MV Liquidator | Liquidator | 2026 | — | — |
AB External Signatory | External Signatory | 2026 | — | — |
DA Deputy Chief Executive Officer | Deputy Chief Executive Officer | 2022 | — | — |
LO Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
AE Liquidator | Liquidator | 2026 | — | — |
RA Audit | Audit | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2022 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Immunscape AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Emma Johanna Åström | External Signatory | 0 companies |
| Sofie Margareta Lundberg | External Signatory | 0 companies |
| Emma Frida Ramona Melander Vängbo | External Signatory | 0 companies |
| Mona Veronica Vesterberg | Liquidator | 0 companies |
| Anna Birgitta Emanuelsson | External Signatory | 0 companies |
| David Allan Mathias Färnegårdh | Deputy Chief Executive Officer | 0 companies |
| Lars Ole Öhman | Chief Executive Officer | 0 companies |
| Anna Elisabeth Adolfsson | Liquidator | 0 companies |
| Roger Andreas Ehrman | Audit | 0 companies |
| Konrad Forster Koehler | Chairman | 0 companies |